Baird served as co-manager on this offering
AboutKaryopharm Therapeutics, Inc. (“Karyopharm”) (NASDAQ:KPTI) recently completed an underwritten public offering of 7,187,500 shares of its common stock at a price to the public of $24.00 per share, which includes the exercise in full by the underwriters of their option to purchase an additional 937,500 shares of common stock. The gross proceeds to Karyopharm from the offering are expected to be $172.5 million.
Karyopharm is an oncology-focused pharmaceutical company dedicated to the discovery, development and commercialization of novel first-in-class drugs directed against nuclear export and related targets for the treatment of cancer and other major diseases. Karyopharm's SINE compounds function by binding with and inhibiting the nuclear export protein XPO1. In addition to single-agent and combination activity against a variety of human cancers, SINE compounds have also shown biological activity in models of neurodegeneration, inflammation, autoimmune disease, certain viruses and wound-healing. Karyopharm has several investigational programs in clinical or preclinical development. Karyopharm Therapeutics, Inc. is headquartered in Newton, Massachusetts.
CONTACT US TO LEARN MORE
- March 2020
- Karyopharm Therapeutics Inc.
- Target Location
- North America